      6         ADVERSE REACTIONS  

  The following adverse reactions are discussed in more detail in other sections of the prescribing information:



 *   Vision≠B-OSE_Labeled_AE   Loss≠I-OSE_Labeled_AE  [see    BOXED WARNING     and     Warnings and Precautions (5.1)    ]  
 *   Magnetic≠B-OSE_Labeled_AE   Resonance≠I-OSE_Labeled_AE   Imaging≠I-OSE_Labeled_AE   (≠I-OSE_Labeled_AE  MRI≠I-OSE_Labeled_AE  )≠I-OSE_Labeled_AE   Abnormalities≠I-OSE_Labeled_AE  in Infants [see    Warnings and Precautions (5.3)    ]  
 *   Neurotoxicity≠B-OSE_Labeled_AE  [see    Warnings and Precautions (5.4)    ]  
 *   Suicidal≠B-OSE_Labeled_AE   Behavior≠I-OSE_Labeled_AE  and Ideation [see    Warnings and Precautions (5.5)    ]  
 *   Withdrawal≠B-NonOSE_AE  of Antiepileptic Drugs (AEDs) [see    Warnings and Precautions (5.6)    ]  
 *   Anemia≠B-OSE_Labeled_AE  [see    Warnings and Precautions (5.7)    ]  
 *   Somnolence≠B-OSE_Labeled_AE  and  Fatigue≠B-OSE_Labeled_AE  [see    Warnings and Precautions (5.8)    ]  
 *   Peripheral≠B-OSE_Labeled_AE   Neuropathy≠I-OSE_Labeled_AE  [see    Warnings and Precautions (5.9)    ]  
 *   Weight≠B-OSE_Labeled_AE   Gain≠I-OSE_Labeled_AE  [see    Warnings and Precautions (5.10)    ]  
 *   Edema≠B-OSE_Labeled_AE  [see    Warnings and Precautions (5.11)    ]  
      EXCERPT:     Refractory    Complex Partial Seizures  
 

 Most common adverse reactions in controlled studies include:



 *  Adults >16 years of age (change of >=5% over placebo): in addition to permanent vision loss, fatigue, somnolence, nystagmus, tremor, vision blurred, memory impairment, weight gain, arthralgia, abnormal coordination, and confusional state  (  6.1  ) 
 *  Pediatrics 10 to 16 years of age (change of >=5% over placebo): increased weight, upper respiratory tract infection, tremor, fatigue, aggression and diplopia   (  6.1  )  
      Infantile Spasms         (incidence >5%)  
 

 *  Somnolence, bronchitis, ear infection, and otitis media acute (  6.1  ) 
      To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  
 

 

    6.1          Clinical Trial    Experience  

  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.



     Adverse    Reactions    in U    .    S    .    and Primary Non-U    .    S    .    Clinical Studies    In U.S. and primary non-U.S. clinical studies of 4,079 SABRIL treated patients, the most commonly observed (>=5%) adverse reactions associated with the use of SABRIL in combination with other AEDs were  headache≠B-OSE_Labeled_AE ,  somnolence≠B-OSE_Labeled_AE ,  fatigue≠B-OSE_Labeled_AE ,  dizziness≠B-OSE_Labeled_AE ,  convulsion≠B-OSE_Labeled_AE ,  nasopharyngitis≠B-OSE_Labeled_AE ,  weight≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE ,  upper≠B-OSE_Labeled_AE   respiratory≠I-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE ,  visual≠B-OSE_Labeled_AE   field≠I-OSE_Labeled_AE   defect≠I-OSE_Labeled_AE ,  depression≠B-OSE_Labeled_AE ,  tremor≠B-OSE_Labeled_AE ,  nystagmus≠B-OSE_Labeled_AE ,  nausea≠B-OSE_Labeled_AE ,  diarrhea≠B-OSE_Labeled_AE ,  memory≠B-OSE_Labeled_AE   impairment≠I-OSE_Labeled_AE ,  insomnia≠B-OSE_Labeled_AE ,  irritability≠B-OSE_Labeled_AE ,  coordination≠B-OSE_Labeled_AE   abnormal≠I-OSE_Labeled_AE ,  vision≠B-OSE_Labeled_AE   blurred≠I-OSE_Labeled_AE ,  diplopia≠B-OSE_Labeled_AE ,  vomiting≠B-OSE_Labeled_AE ,  influenza≠B-OSE_Labeled_AE ,  pyrexia≠B-OSE_Labeled_AE , and  rash≠B-OSE_Labeled_AE .



 The adverse reactions most commonly associated with SABRIL treatment discontinuation in >=1% of patients were  convulsion≠B-OSE_Labeled_AE  and  depression≠B-OSE_Labeled_AE .



 In patients with  infantile≠B-Not_AE_Candidate   spasms≠I-Not_AE_Candidate , the adverse reactions most commonly associated with SABRIL treatment discontinuation in >=1% of patients were  infections≠B-OSE_Labeled_AE ,  status≠B-OSE_Labeled_AE   epilepticus≠I-OSE_Labeled_AE ,  developmental≠B-OSE_Labeled_AE   coordination≠I-OSE_Labeled_AE   disorder≠I-OSE_Labeled_AE ,  dystonia≠B-OSE_Labeled_AE ,  hypotonia≠B-OSE_Labeled_AE ,  hypertonia≠B-OSE_Labeled_AE ,  weight≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE , and  insomnia≠B-OSE_Labeled_AE .



     Most Common        Adverse        Reactions        in Controlled Clinical Trials    



      Refractory≠B-Not_AE_Candidate   C≠I-Not_AE_Candidate          omplex≠I-Not_AE_Candidate   Partial≠I-Not_AE_Candidate   Seizures≠I-Not_AE_Candidate       Adults       Table 5 lists the treatment emergent adverse reactions that occurred in >=2% and more than one patient per SABRIL treated group and that occurred more frequently than in placebo patients from 2 U.S. add-on clinical studies of  refractory≠B-Not_AE_Candidate   CPS≠I-Not_AE_Candidate  in adults. 




   Table 5. Treatment Emergent Adverse Reactions Occurring in >=2% and More than One Patient per SABRIL-Treated Group and More Frequently than in Placebo Patients (Studies 024 and 025)     
                     SABRIL dosage(mg/day)                    
    Body System         Adverse Reaction     3000[N=134]%     6000[N=43]%      Placebo[N=135]%   
       Ear≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                                                         
         Tinnitus≠B-OSE_Labeled_AE       2                0                1             
         Vertigo≠B-OSE_Labeled_AE        2                5                1             
       Eye≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                                                         
         Vision≠B-OSE_Labeled_AE   blurred≠I-OSE_Labeled_AE      13               16                5             
         Diplopia≠B-OSE_Labeled_AE       7               16                3             
         Asthenopia≠B-OSE_Labeled_AE       2                 2               0             
         Eye≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE       0                 5               0             
       Gastrointestinal≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                                                         
         Diarrhoea≠B-OSE_Labeled_AE      10               16                7             
         Nausea≠B-OSE_Labeled_AE        10                 2               8             
         Vomiting≠B-OSE_Labeled_AE       7                 9               6             
         Constipation≠B-OSE_Labeled_AE       8                 5               3             
         Abdominal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE   upper≠I-OSE_Labeled_AE       5                 5               1             
         Dyspepsia≠B-OSE_Labeled_AE       4                 5               3             
         Stomach≠B-OSE_Labeled_AE   discomfort≠I-OSE_Labeled_AE       4                 2               1             
         Abdominal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE       3                 2               1             
         Toothache≠B-OSE_Labeled_AE       2                 5               2             
         Abdominal≠B-OSE_Labeled_AE   distension≠I-OSE_Labeled_AE       2                 0               1             
       General≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                                                         
         Fatigue≠B-OSE_Labeled_AE       23               40               16             
         Gait≠B-OSE_Labeled_AE   disturbance≠I-OSE_Labeled_AE      6                12                7             
         Asthenia≠B-OSE_Labeled_AE      5                 7                1             
         Oedema≠B-OSE_Labeled_AE   peripheral≠I-OSE_Labeled_AE      5                 7                1             
         Fever≠B-OSE_Labeled_AE         4                 7                3             
         Chest≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE      1                 5                1             
         Thirst≠B-OSE_Labeled_AE        2                 0                0             
         Malaise≠B-OSE_Labeled_AE       0                 5                0             
       Infections≠B-NonOSE_AE                                                         
         Nasopharyngitis≠B-OSE_Labeled_AE      14                9               10             
         Upper≠B-OSE_Labeled_AE   respiratory≠I-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE      7                 9                6             
         Influenza≠B-OSE_Labeled_AE      5                 7                4             
         Urinary≠B-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE      4                 5                0             
         Bronchitis≠B-OSE_Labeled_AE      0                 5                1             
       Injury≠B-NonOSE_AE                                                           
         Contusion≠B-OSE_Labeled_AE      3                 5                2             
         Joint≠B-OSE_Labeled_AE   sprain≠I-OSE_Labeled_AE      1                 2                1             
         Muscle≠B-OSE_Labeled_AE   strain≠I-OSE_Labeled_AE      1                 2                1             
         Wound≠B-OSE_Labeled_AE   secretion≠I-OSE_Labeled_AE      0                 2                0             
       Metabolism≠B-NonOSE_AE   and≠I-NonOSE_AE   Nutrition≠I-NonOSE_AE   Disorders≠I-NonOSE_AE                                                         
         Increased≠B-OSE_Labeled_AE   appetite≠I-OSE_Labeled_AE      1                  5              1              
         Weight≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE      6                14               3              
       Musculoskeletal≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                                                         
         Arthralgia≠B-OSE_Labeled_AE      10                5               3              
         Back≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE       4                7               2              
         Pain≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   extremity≠I-OSE_Labeled_AE       6                2               4              
         Myalgia≠B-OSE_Labeled_AE        3                5               1              
         Muscle≠B-OSE_Labeled_AE   twitching≠I-OSE_Labeled_AE       1                9               1              
         Muscle≠B-OSE_Labeled_AE   spasms≠I-OSE_Labeled_AE       3                0               1              
       Nervous≠B-NonOSE_AE   System≠I-NonOSE_AE   Disorders≠I-NonOSE_AE                                                         
         Headache≠B-OSE_Labeled_AE      33               26               31             
         Somnolence≠B-OSE_Labeled_AE      22               26               13             
         Dizziness≠B-OSE_Labeled_AE      24               26               17             
         Nystagmus≠B-OSE_Labeled_AE      13               19                9             
         Tremor≠B-OSE_Labeled_AE        15               16                8             
         Memory≠B-OSE_Labeled_AE   impairment≠I-OSE_Labeled_AE       7               16                3             
         Coordination≠B-OSE_Labeled_AE   abnormal≠I-OSE_Labeled_AE       7               16                2             
         Disturbance≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   attention≠I-OSE_Labeled_AE       9                0                1             
         Sensory≠B-OSE_Labeled_AE   disturbance≠I-OSE_Labeled_AE       4                7                2             
         Hyporeflexia≠B-OSE_Labeled_AE       4                5                1             
         Paraesthesia≠B-OSE_Labeled_AE       7                2                1             
         Lethargy≠B-OSE_Labeled_AE       4                7                2             
         Hyperreflexia≠B-OSE_Labeled_AE       4                2                3             
         Hypoaesthesia≠B-OSE_Labeled_AE       4                5                1             
         Sedation≠B-OSE_Labeled_AE       4                0                0             
         Status≠B-OSE_Labeled_AE   epilepticus≠I-OSE_Labeled_AE       2                5                0             
         Dysarthria≠B-OSE_Labeled_AE       2                2                1             
         Postictal≠B-OSE_Labeled_AE   state≠I-OSE_Labeled_AE       2                0                1             
         Sensory≠B-OSE_Labeled_AE   loss≠I-OSE_Labeled_AE       0                5                0             
       Psychiatric≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                                                         
         Irritability≠B-OSE_Labeled_AE       7               23                7             
         Depression≠B-OSE_Labeled_AE       6               14                3             
         Confusional≠B-OSE_Labeled_AE   state≠I-OSE_Labeled_AE       4               14                1             
         Anxiety≠B-OSE_Labeled_AE        4                0                3             
         Depressed≠B-OSE_Labeled_AE   mood≠I-OSE_Labeled_AE       5                0                1             
         Thinking≠B-OSE_Labeled_AE   abnormal≠I-OSE_Labeled_AE       3                7                0             
         Abnormal≠B-OSE_Labeled_AE   behaviour≠I-OSE_Labeled_AE       3                5                1             
         Expressive≠B-OSE_Labeled_AE   language≠I-OSE_Labeled_AE   disorder≠I-OSE_Labeled_AE       1                7                1             
         Nervousness≠B-OSE_Labeled_AE       2                5                2             
         Abnormal≠B-OSE_Labeled_AE   dreams≠I-OSE_Labeled_AE       1                5                1             
       Reproductive≠B-NonOSE_AE   System≠I-NonOSE_AE                                                         
         Dysmenorrhoea≠B-OSE_Labeled_AE      9                 5                3             
         Erectile≠B-OSE_Labeled_AE   dysfunction≠I-OSE_Labeled_AE      0                 5                0             
       Respiratory≠B-NonOSE_AE   and≠I-NonOSE_AE   Thoracic≠I-NonOSE_AE   Disorders≠I-NonOSE_AE                                                         
         Pharyngolaryngeal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE       7               14               5              
         Cough≠B-OSE_Labeled_AE          2               14               7              
         Pulmonary≠B-OSE_Labeled_AE   congestion≠I-OSE_Labeled_AE       0                5               1              
         Sinus≠B-OSE_Labeled_AE   headache≠I-OSE_Labeled_AE       6                2               1              
       Skin≠B-NonOSE_AE   and≠I-NonOSE_AE   Subcutaneous≠I-NonOSE_AE   Tissue≠I-NonOSE_AE   Disorders≠I-NonOSE_AE                                                         
         Rash≠B-OSE_Labeled_AE           4                5               4              
              Pediatrics 10 to 16 years of age    Table 6 lists adverse reactions from controlled clinical studies of pediatric patients receiving SABRIL or placebo as add-on therapy for refractory  complex≠B-Not_AE_Candidate   partial≠I-Not_AE_Candidate   seizures≠I-Not_AE_Candidate .  Adverse reactions that are listed occurred in at least 2% of SABRIL treated patients and more frequently than placebo. The median SABRIL dose was 49.4 mg/kg, (range of 8.0 - 105.9 mg/kg).
 


   Table 6.  Treatment-Emergent Adverse Reactions Reported  by >=2% of Pediatric CPS Patients (10 to 16 years of age)  Treated with SABRIL and Higher than Placebo     
   Body System       Adverse Reaction  All SABRIL[N=109]%  Placebo[N=46]%    
     Eye≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                                        
       Diplopia≠B-OSE_Labeled_AE      5                0                
       Vision≠B-OSE_Labeled_AE   blurred≠I-OSE_Labeled_AE    3                0                
     Gastrointestinal≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                                        
       Diarrhoea≠B-OSE_Labeled_AE     6                2                
       Abdominal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE   upper≠I-OSE_Labeled_AE    3                0                
       Constipation≠B-OSE_Labeled_AE    3                2                
     General≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                                        
       Fatigue≠B-OSE_Labeled_AE       9                4                
     Infections≠B-NonOSE_AE   and≠I-NonOSE_AE   Infestations≠I-NonOSE_AE                                        
       Upper≠B-OSE_Labeled_AE   respiratory≠I-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE    10               4                
       Influenza≠B-OSE_Labeled_AE     6                2                
       Otitis≠B-OSE_Labeled_AE   media≠I-OSE_Labeled_AE    6                2                
     Investigations≠B-NonOSE_AE                                        
       Weight≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE    17               2                
     Nervous≠B-NonOSE_AE   System≠I-NonOSE_AE   Disorders≠I-NonOSE_AE                                        
       Somnolence≠B-OSE_Labeled_AE    6                2                
       Tremor≠B-OSE_Labeled_AE        6                0                
       Nystagmus≠B-OSE_Labeled_AE     5                2                
       Psychomotor≠B-OSE_Labeled_AE   hyperactivity≠I-OSE_Labeled_AE    4                2                
     Psychiatric≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                                        
       Abnormal≠B-OSE_Labeled_AE   behavior≠I-OSE_Labeled_AE    6                2                
       Aggression≠B-OSE_Labeled_AE    5                0                
       Disorientation≠B-OSE_Labeled_AE   4                0                 
     Reproduction≠B-NonOSE_AE   and≠I-NonOSE_AE   Breast≠I-NonOSE_AE   Disorders≠I-NonOSE_AE                                        
       Dysmenorrhea≠B-OSE_Labeled_AE    3               0                 
     Skin≠B-NonOSE_AE   and≠I-NonOSE_AE   Subcutaneous≠I-NonOSE_AE   Tissue≠I-NonOSE_AE   Disorders≠I-NonOSE_AE                                        
       Acne≠B-OSE_Labeled_AE          3               0                 
              Infantile≠B-Not_AE_Candidate   Spasms≠I-Not_AE_Candidate     In a randomized, placebo-controlled IS study with a 5 day double-blind treatment phase (n=40), the adverse events reported by >5% of patients receiving SABRIL and that occurred more frequently than in placebo patients, were  somnolence≠B-OSE_Labeled_AE  (SABRIL 45%,   placebo  30%),  bronchitis≠B-OSE_Labeled_AE  (SABRIL 30%,  placebo  15%),  ear≠B-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE  (SABRIL 10%,   placebo  5%), and  otitis≠B-OSE_Labeled_AE   media≠I-OSE_Labeled_AE   acute≠I-OSE_Labeled_AE  SABRIL 10%,   placebo  0%).
 

 In a dose response study of low-dose (18-36 mg/kg/day) versus high-dose (100-148 mg/kg/day) vigabatrin, no clear correlation between dose and incidence of adverse events was observed. The treatment emergent adverse reactions (>=5% in either dose group) are summarized in Table 7.




    Table 7.  Treatment Emergent Adverse Reactions Occurring in >=5% of Infantile Spasms Patients     
  
                   SABRILLow Dose   SABRIL High Dose   
    Body System       Adverse Reaction   [N=114]%         [N=108]%         
     Eye≠B-NonOSE_AE   Disorders≠I-NonOSE_AE  (other than field or acuity changes)                                       
       Strabismus≠B-OSE_Labeled_AE    5                5                
       Conjunctivitis≠B-OSE_Labeled_AE    5                2                
     Gastrointestinal≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                                        
       Vomiting≠B-OSE_Labeled_AE      14               20               
       Constipation≠B-OSE_Labeled_AE    14               12               
       Diarrhea≠B-OSE_Labeled_AE      13               12               
     General≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                                        
       Fever≠B-OSE_Labeled_AE         29               19               
     Infections≠B-NonOSE_AE                                        
       Upper≠B-OSE_Labeled_AE   respiratory≠I-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE    51               46               
       Otitis≠B-OSE_Labeled_AE   media≠I-OSE_Labeled_AE    44               30               
       Viral≠B-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE    20               19               
       Pneumonia≠B-OSE_Labeled_AE     13               11               
       Candidiasis≠B-OSE_Labeled_AE    8                3                
       Ear≠B-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE    7                14               
       Gastroenteritis≠B-OSE_Labeled_AE   viral≠I-OSE_Labeled_AE    6                5                
       Sinusitis≠B-OSE_Labeled_AE     5                9                
       Urinary≠B-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE    5                6                
       Influenza≠B-OSE_Labeled_AE     5                3                
       Croup≠B-OSE_Labeled_AE   infectious≠I-OSE_Labeled_AE    5                1                
      Metabolism≠B-NonOSE_AE   &≠I-NonOSE_AE   Nutrition≠I-NonOSE_AE   Disorders≠I-NonOSE_AE                                        
       Decreased≠B-OSE_Labeled_AE   appetite≠I-OSE_Labeled_AE    9                7                
      Nervous≠B-NonOSE_AE   System≠I-NonOSE_AE   Disorders≠I-NonOSE_AE                                        
       Sedation≠B-OSE_Labeled_AE      19               17               
       Somnolence≠B-OSE_Labeled_AE    17               19               
       Status≠B-OSE_Labeled_AE   epilepticus≠I-OSE_Labeled_AE    6                4                
       Lethargy≠B-OSE_Labeled_AE      5                7                
       Convulsion≠B-OSE_Labeled_AE    4                7                
       Hypotonia≠B-OSE_Labeled_AE     4                6                
     Psychiatric≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                                        
       Irritability≠B-OSE_Labeled_AE    16               23               
       Insomnia≠B-OSE_Labeled_AE      10               12               
     Respiratory≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                                        
       Nasal≠B-OSE_Labeled_AE   congestion≠I-OSE_Labeled_AE    13               4                
       Cough≠B-OSE_Labeled_AE         3                8                
     Skin≠B-NonOSE_AE   and≠I-NonOSE_AE   Subcutaneous≠I-NonOSE_AE   Tissue≠I-NonOSE_AE   Disorders≠I-NonOSE_AE                                        
       Rash≠B-OSE_Labeled_AE          8                11               
             6.2       Post Marketing Experience  
   The following adverse reactions have been reported during post approval use of SABRIL worldwide. All adverse reactions that are not listed above as adverse reactions reported in clinical trials, that are not relatively common in the population and are not too vague to be useful are listed in this section. These reactions are reported voluntarily from a population of uncertain size; therefore, it is not possible to estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions are categorized by system organ class.



      Birth≠B-NonOSE_AE   Defects≠I-NonOSE_AE         :          Congenital≠B-OSE_Labeled_AE   cardiac≠I-OSE_Labeled_AE   defects≠I-OSE_Labeled_AE ,  congenital≠B-OSE_Labeled_AE   external≠I-OSE_Labeled_AE   ear≠I-OSE_Labeled_AE   anomaly≠I-OSE_Labeled_AE ,  congenital≠B-OSE_Labeled_AE   hemangioma≠I-OSE_Labeled_AE ,  congenital≠B-OSE_Labeled_AE   hydronephrosis≠I-OSE_Labeled_AE ,  congenital≠B-OSE_Labeled_AE   male≠I-OSE_Labeled_AE   genital≠I-OSE_Labeled_AE   malformation≠I-OSE_Labeled_AE ,  congenital≠B-OSE_Labeled_AE   oral≠I-OSE_Labeled_AE   malformation≠I-OSE_Labeled_AE ,  congenital≠B-OSE_Labeled_AE   vesicoureteric≠I-OSE_Labeled_AE   reflux≠I-OSE_Labeled_AE , dentofacial anomaly, dysmorphism, fetal anticonvulsant syndrome, hamartomas, hip dysplasia, limb malformation, limb reduction defect, low set ears, renal aplasia, retinitis pigmentosa, supernumerary nipple, talipes



      Ear≠B-NonOSE_AE          Disorders≠I-NonOSE_AE         :     Deafness≠B-OSE_Labeled_AE 



      Endocrine≠B-NonOSE_AE          Disorders≠I-NonOSE_AE         :          Delayed≠B-OSE_Labeled_AE   puberty≠I-OSE_Labeled_AE 



      Gastrointestinal≠B-NonOSE_AE          Disorders≠I-NonOSE_AE         :     Gastrointestinal≠B-OSE_Labeled_AE   hemorrhage≠I-OSE_Labeled_AE ,  esophagitis≠B-OSE_Labeled_AE 



      General≠B-NonOSE_AE          Disorders≠I-NonOSE_AE         :      Developmental≠B-OSE_Labeled_AE   delay≠I-OSE_Labeled_AE ,  facial≠B-OSE_Labeled_AE   edema≠I-OSE_Labeled_AE ,  malignant≠B-OSE_Labeled_AE   hyperthermia≠I-OSE_Labeled_AE ,  multi≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  organ≠I-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE 



      Hepatobiliary≠B-NonOSE_AE          Disorders≠I-NonOSE_AE         :      Cholestasis≠B-OSE_Labeled_AE 



      Nervous≠B-NonOSE_AE   System≠I-NonOSE_AE          Disorders≠I-NonOSE_AE         :      Dystonia≠B-OSE_Labeled_AE ,  encephalopathy≠B-OSE_Labeled_AE ,  hypertonia≠B-OSE_Labeled_AE ,  hypotonia≠B-OSE_Labeled_AE ,  muscle≠B-OSE_Labeled_AE   spasticity≠I-OSE_Labeled_AE ,  myoclonus≠B-OSE_Labeled_AE ,  optic≠B-OSE_Labeled_AE   neuritis≠I-OSE_Labeled_AE ,  dyskinesia≠B-OSE_Labeled_AE 



      Psychiatric≠B-NonOSE_AE          Disorders≠I-NonOSE_AE         :          Acute≠B-OSE_Labeled_AE   psychosis≠I-OSE_Labeled_AE ,  apathy≠B-OSE_Labeled_AE ,  delirium≠B-OSE_Labeled_AE ,  hypomania≠B-OSE_Labeled_AE ,  neonatal≠B-OSE_Labeled_AE   agitation≠I-OSE_Labeled_AE ,  psychotic≠B-OSE_Labeled_AE   disorder≠I-OSE_Labeled_AE 



      Respiratory≠B-NonOSE_AE   Disorders≠I-NonOSE_AE :     Laryngeal≠B-OSE_Labeled_AE   edema≠I-OSE_Labeled_AE ,  pulmonary≠B-OSE_Labeled_AE   embolism≠I-OSE_Labeled_AE ,  respiratory≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE ,  stridor≠B-OSE_Labeled_AE 



      Skin≠B-NonOSE_AE   and≠I-NonOSE_AE   Subcutaneous≠I-NonOSE_AE   Tissue≠I-NonOSE_AE   Disorders≠I-NonOSE_AE :     Angioedema≠B-OSE_Labeled_AE ,  maculo≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  papular≠I-OSE_Labeled_AE   rash≠I-OSE_Labeled_AE ,  pruritus≠B-OSE_Labeled_AE ,  Stevens≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  Johnson≠I-OSE_Labeled_AE   syndrome≠I-OSE_Labeled_AE  (SJS),  toxic≠B-OSE_Labeled_AE   epidermal≠I-OSE_Labeled_AE   necrolysis≠I-OSE_Labeled_AE  (TEN) 
